- Clearmind Medicine (CMND) has announced positive pre-clinical results demonstrating the efficacy of its drug candidate MEAI
- The pre-clinical results demonstrated that MEAI was efficacious in treating obesity and metabolic syndrome
- The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20 per cent
- Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company
- Clearmind Medicine Inc. was up 11.30 per cent, trading at $4.53 at 11:26 ET
Clearmind Medicine (CMND) has announced positive pre-clinical results demonstrating the efficacy of its drug candidate MEAI.
The pre-clinical results demonstrated that MEAI was efficacious in treating obesity and metabolic syndrome.
The study was conducted at the Hebrew University of Jerusalem as part of a collaboration established with the university’s technology transfer company, Yissum.
It included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation, as well as food consumption patterns.
Three groups of rodents were used: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20 per cent while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed.
Furthermore, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high-fat, untreated group.
Also, a significant reduction in sucrose preference was observed following the administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli.
Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behaviour or excessive consumption of sweet foods.
“We’re very excited about these results, which suggest that MEAI may be effective in treating obesity, one of the world’s most pressing problems,” noted Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.
“These additional positive results in our treatment of addictions, once again, indicate MEAI’s potential to become a viable treatment for a variety of disorders,” she added.
The study was led by Prof. Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research and Dr. Saja Baraghithy, Ph.D.
According to the World Health Organization, 1 billion people, accounting for more than 30 per cent of the global population, are overweight. About 5 per cent of deaths worldwide are the result of obesity.
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, including alcohol use disorder.
The Hebrew University of Jerusalem is Israel’s leading academic and research institution.
Yissum is the technology transfer company of The Hebrew University of Jerusalem.
Clearmind Medicine Inc. (CMND) was up 11.30 per cent, trading at $4.53 at 11:26 ET.
